Pfizer/BioNTech vaccine appears effective against mutation in new coronavirus variants - study

By Michael Erman NEW YORK (Reuters) - Pfizer Inc and BioNTech's COVID-19 vaccine appears able to protect against a key mutation in the highly transmissible new variants of the coronavirus discovered in Britain and South Africa, according to a laboratory study conducted by the U.S. drugmaker

Reuters January 09, 2021 00:12:05 IST
Pfizer/BioNTech vaccine appears effective against mutation in new coronavirus variants - study

coronavirus variants - study" src="https://images.firstpost.com/wp-content/uploads/reuters/01-2021/09/2021-01-08T033447Z_1_LYNXMPEH0705I_RTROPTP_2_HEALTH-CORONAVIRUS-MEXICO-VACCINE.jpg" alt="PfizerBioNTech vaccine appears effective against mutation in new coronavirus variants study" width="300" height="225" />

By Michael Erman

NEW YORK (Reuters) - Pfizer Inc and BioNTech's COVID-19 vaccine appears able to protect against a key mutation in the highly transmissible new variants of the coronavirus discovered in Britain and South Africa, according to a laboratory study conducted by the U.S. drugmaker.

The study by Pfizer and scientists from the University of Texas Medical Branch, which has not yet been peer-reviewed, indicated the vaccine was effective in neutralizing variants with the so-called N501Y mutation, situated on a portion of the virus that it uses to enter and infect cells.

All of the vaccines already approved or in development use this outer portion of the virus, known as the spike protein, to train the body to recognize the virus and make virus-neutralizing antibodies.

The N501Y mutation is linked to greater transmissibility, and scientists have expressed concerns it could also allow the virus to escape the neutralizing antibodies produced in response to the vaccine, said Phil Dormitzer, one of Pfizer's top viral vaccine scientists.

The first results of tests on some of the key variants of concern offer some hope as Britain and other countries try to tame the more infectious variants, which authorities believe are driving a surge in infections that could overwhelm healthcare systems.

Although all viruses mutate constantly, scientists are concerned about the mutations first discovered in Britain and South Africa because they are believed to be capable of altering key functions of the virus.

The Pfizer study was conducted on blood taken from people who had been given the vaccine. Its findings are limited because it does not look at the full set of mutations found in either of the new variants of the rapidly spreading virus.

Dormitzer said it was encouraging that the vaccine appears effective against the mutation, as well as against 15 other mutations the company has previously tested.

"So we've now tested 16 different mutations, and none of them have really had any significant impact. That's the good news," he said. "That doesn't mean that the 17th won't."

The study still does not address a worrisome mutation in the South African variant, called the E484K mutation.

CONSTANT MONITORING

The U.S. researchers plan to run similar tests to see whether the vaccine protects against other mutations from the variants from Britain and South Africa. They hope to have data within weeks.

The variants are said by scientists to be more transmissible than previously dominant ones, but they are not thought to cause more serious illness.

Independent experts gave a cautious welcome to the Pfizer study findings, but said the situation needs constant vigilance.

Paul Hunter, a professor in medicine at Britain's University of East Anglia, said "the jury is still out on the impact of the South African variant on vaccine efficacy."

Deborah Dunn-Walters, a professor of immunology at Surrey University in Britain, said it was "reassuring" that Pfizer is closely monitoring variants.

Ongoing testing will be needed, experts said, to allay concerns about whether vaccines being given to millions of people in the fight against the pandemic will protect them as the virus mutates. COVID-19 has killed more than 1.8 million people worldwide.

"The evidence is not conclusive but there is a lot to indicate that the existing mRNA vaccines do cover the new variants. That is the good news," said Andreas Bergthaler, principal investigator at the Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna.

TESTS AND TWEAKS

AstraZeneca, Moderna and CureVac are also testing whether their shots will protect against the fast-spreading coronavirus variants. They have said they expect them to be effective, but have not said when study results will be published.

The Pfizer/BioNTech COVID-19 vaccine and the one from Moderna Inc, which both use synthetic messenger RNA technology, or mRNA, can be quickly adapted to address new mutations in the coronavirus if necessary. Scientists have suggested the changes could be made in as little as six weeks.

Eleanor Riley, a professor of immunology and infectious disease at Edinburgh University, said similar studies would need to be repeated as new mutations appear. "It may be necessary to tweak the vaccine over time," she said.

A senior British lawmaker expressed concerns in an interview on Friday that COVID-19 vaccines might not work properly against the South African variant. He was not responding to questions about Friday's data.

(Additional reporting by Kate Kelland in London, Julie Steenhuysen in Chicago and Doug Busvine in Berlin; Writing by Josephine Mason; Editing by Bill Berkrot, Edwina Gibbs, Timothy Heritage and Dan Grebler)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Target holiday sales jump 17% as shoppers splurge online
Business

Target holiday sales jump 17% as shoppers splurge online

By Uday Sampath Kumar (Reuters) - Target Corp reported a 17.2% rise in comparable sales for the holiday season on Wednesday as its online sales more than doubled, thanks to faster deliveries and higher demand for home goods, electronics and beauty products.

S&P 500, Nasdaq tick higher on Intel boost
Business

S&P 500, Nasdaq tick higher on Intel boost

By Medha Singh and Devik Jain (Reuters) - The S&P 500 and the Nasdaq rose in choppy trading on Wednesday as Intel shares jumped thanks to a change in management while broader sentiment was muted after a recent run to record highs. Intel said it would replace Chief Executive Officer Bob Swan with VMware Inc CEO Pat Gelsinger next month

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses
Business

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses

By Danny Ramos LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine. President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population. Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.